Breaking News, Collaborations & Alliances

XOMA, Servier, Boehringer in Bio-Manufacturing Pact

Boehringer to produce gevokizumab at Biberach

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

XOMA Corp. and partner Les Laboratoires Servier (Servier) have entered into an agreement with Boehringer Ingelheim to transfer XOMA’s technology and process for the commercial manufacture of gevokizumab, XOMA’s interleukin 1-beta (IL-1β) allosteric modulating antibody.   Gevokizumab is in Phase III trials for patients with non-infectious uveitis (NIU). Servier will also conduct a Phase III trial in patients with Behcet’s uveitis. Upon completion of the transfer and the establis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters